Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this clinical trial is to assess and compare the effect of insulin detemir in combination with liraglutide and metformin versus insulin detemir in combination with insulin aspart and metformin in subjects with very uncontrolled Type 2 Diabetes (A1c > 10%).
The aim of this study is to compare a GLP-1 plus basal insulin and metformin treatment regimen to a basal-bolus plus metformin treatment regimen in patients with very uncontrolled (HbA1c>10%) type 2 diabetes. The investigators will compare the two regimens with respect to efficacy in improving glycemic control, rate of hypoglycemia, change in weight, effect on patient quality of life, treatment burden, physician time, as well as healthcare related cost. The investigators hypothesize that at 26 weeks from randomization the two treatment regimens will have similar percentage of patients reaching A1c levels <7.0%, while more patients on the GLP-1 plus basal insulin strategy will achieve the composite end point of A1c levels <7.0% without severe hypoglycemia or significant weight gain.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control: Metformin, Insulin Detemir, Insulin Aspart | Active Comparator | Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician |
|
| Metformin, insulin determir, Liraglutide | Active Comparator | Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol"; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Metformin | Drug | Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mean Change From Randomization in A1c at Week 26 | Change in glycosylated Hemoglobin A1c (A1c) from randomization to 26 weeks of therapy | Baseline and Week 26 |
| Measure | Description | Time Frame |
|---|---|---|
| Composite End-point | Percentage of participants with glycosylated Hemoglobin A1c (A1c)<8% AND no documented severe hypoglycemia (<56 mg/dL) during the study AND no significant weight gain (>3% from baseline) | Week 0 (Randomization) , Week 26 |
| Percentage of Participants Reaching Target A1c of <7% at Week 26 |
Not provided
Inclusion Criteria:
1. Clinical diagnosis of type 2 diabetes with confirmed HbA1c level >10% at time of enrollment, regardless of prior or current treatment regimens, or time since diagnosis.
Exclusion Criteria:
Age <18 as the feasibility and safety of this treatment regimen should be first established in the adult population; if successful, a subsequent pediatric study will be proposed;
Type 1 diabetes as purposefully withholding meal-time insulin is contraindicated;
Clinical state requiring inpatient admission/treatment;
Contraindication or strong cautions to any of the study medications:
Any serious or unstable medical condition as it would interfere with treatment assignment as well as outcome measurement;
Any scheduled elective procedures/surgeries;
Active infections, including osteomyelitis;
Not willing to participate, unable to keep projected appointments, unwillingness to receive injectable treatment; unwillingness to perform 7-point glucose profiles over 2 consecutive days the weeks prior to Randomization (visit 1)and the week prior to visit 6
Non English speaking.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ildiko Lingvay | University of Texas Southwestern Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UT Southwestern Medical Center | Dallas | Texas | 02720 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31803482 | Derived | Patel S, Abreu M, Tumyan A, Adams-Huet B, Li X, Lingvay I. Effect of medication adherence on clinical outcomes in type 2 diabetes: analysis of the SIMPLE study. BMJ Open Diabetes Res Care. 2019 Nov 18;7(1):e000761. doi: 10.1136/bmjdrc-2019-000761. eCollection 2019. |
Not provided
Not provided
Not provided
Total number of subjects consented is 157, total number of subjects randomized is 120, of those 120 only 110 are MITT data set
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Control: Metformin, Insulin Detemir, Insulin Aspart | Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day) Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed. Insulin Aspart: Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG <180 |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | May 6, 2014 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Detemir | Drug | Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed. |
|
|
| Liraglutide | Drug | Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached |
|
|
| Insulin Aspart | Drug | Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG <180 |
|
|
| Week 26 |
| Percentage of Participants Reaching Pre-specified "Treatment Failure" Outcome | Treatment Failure defined as A1c>10% at week 13 (visit 5) | week 13 |
| Mean Change From Randomization in Body Weight | Change in body weight from randomization to end of study. | Week 0 (Randomization) , Week 26 |
| Hypoglycemic Episodes | Percentage of participants experiencing any episodes of documented hypoglycemia defined as CBG reading of <70 mg/dl | Week 0 (Randomization) , Week 2, week 4, week 13, Week 26 |
| Change in Diabetes Quality of Life (DQOL)Questionnaire Score- Least Squares Means | Diabetes Quality of Life (DQOL) questionnaires will be completed by the patient at the randomization and end-of study visits. ALL D-QOL domains are scored on a 1-5 scale, with a lower number representing better quality of life or treatment satisfaction. Outcome reported is difference between mean baseline and mean Week 26 score. | Week 0 (Randomization) , Week 26 |
| Change in Short Form-36 (SF-36) Questionnaire Score | Quality of life questionnaires will be completed by the patient at the randomization and end-of study visits. SF-36 is scored on a 1-100 scale; a higher score represents a better self-assessed health - for all domains. | Week 0 (Randomization) , Week 26 |
| FG001 | Metformin, Insulin Determir, Liraglutide | Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol"; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day) Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day) Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed. Liraglutide: Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Control: Metformin, Insulin Detemir, Insulin Aspart | Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day) Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed. Insulin Aspart: Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG <180 |
| BG001 | Metformin, Insulin Determir, Liraglutide | Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol"; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day) Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day) Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed. Liraglutide: Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race/Ethnicity, Customized | Count of Participants | Participants |
| ||||||||||||||||
| HbA1c | Mean | Standard Deviation | percentage of glycosylated hemoglobin |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Mean Change From Randomization in A1c at Week 26 | Change in glycosylated Hemoglobin A1c (A1c) from randomization to 26 weeks of therapy | Posted | Mean | 95% Confidence Interval | Percentage of glycosylated hemoglobin | Baseline and Week 26 |
|
|
| |||||||||||||||||||||||||||||
| Secondary | Composite End-point | Percentage of participants with glycosylated Hemoglobin A1c (A1c)<8% AND no documented severe hypoglycemia (<56 mg/dL) during the study AND no significant weight gain (>3% from baseline) | Posted | Number | percentage of participants | Week 0 (Randomization) , Week 26 |
| ||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Reaching Target A1c of <7% at Week 26 | Posted | Number | percentage of participants | Week 26 |
| |||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Reaching Pre-specified "Treatment Failure" Outcome | Treatment Failure defined as A1c>10% at week 13 (visit 5) | Posted | Number | percentage of participants | week 13 |
| ||||||||||||||||||||||||||||||||
| Secondary | Mean Change From Randomization in Body Weight | Change in body weight from randomization to end of study. | Posted | Mean | 95% Confidence Interval | kilogram | Week 0 (Randomization) , Week 26 |
| |||||||||||||||||||||||||||||||
| Secondary | Hypoglycemic Episodes | Percentage of participants experiencing any episodes of documented hypoglycemia defined as CBG reading of <70 mg/dl | Posted | Number | percentage of participants | Week 0 (Randomization) , Week 2, week 4, week 13, Week 26 |
| ||||||||||||||||||||||||||||||||
| Secondary | Change in Diabetes Quality of Life (DQOL)Questionnaire Score- Least Squares Means | Diabetes Quality of Life (DQOL) questionnaires will be completed by the patient at the randomization and end-of study visits. ALL D-QOL domains are scored on a 1-5 scale, with a lower number representing better quality of life or treatment satisfaction. Outcome reported is difference between mean baseline and mean Week 26 score. | Posted | Least Squares Mean | 95% Confidence Interval | score on a scale | Week 0 (Randomization) , Week 26 |
| |||||||||||||||||||||||||||||||
| Secondary | Change in Short Form-36 (SF-36) Questionnaire Score | Quality of life questionnaires will be completed by the patient at the randomization and end-of study visits. SF-36 is scored on a 1-100 scale; a higher score represents a better self-assessed health - for all domains. | Posted | Least Squares Mean | 95% Confidence Interval | score on a scale | Week 0 (Randomization) , Week 26 |
|
6 months (Baseline to Week 26)
Adverse events were collected both by self-report as well as review of the electronic health record. Nausea, vomiting, headache, diarrhea and abdominal pain were pre-defined events of special interest and proactively elicited at each visit from all patients.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Control: Metformin, Insulin Detemir, Insulin Aspart | Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day) Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed. Insulin Aspart: Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG <180 | 0 | 56 | 13 | 56 | 40 | 56 |
| EG001 | Metformin, Insulin Determir, Liraglutide | Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol"; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day) Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day) Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed. Liraglutide: Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached | 0 | 54 | 6 | 54 | 50 | 54 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Pneumonia | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Facial Burn | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
| ||
| Urinary Tract Infection | Renal and urinary disorders | Non-systematic Assessment |
| ||
| Respiratory Distress | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
| ||
| Pregnancy | Pregnancy, puerperium and perinatal conditions | Non-systematic Assessment |
| ||
| Small Bowel Obstruction | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| Fall | Investigations | Non-systematic Assessment |
| ||
| chest pain | Cardiac disorders | Non-systematic Assessment |
| ||
| Diabetic Ketoacidosis | Endocrine disorders | Non-systematic Assessment |
| ||
| Osteomyelitis | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
| ||
| hypertension | Cardiac disorders | Non-systematic Assessment |
| ||
| myocardial infarction | Cardiac disorders | Non-systematic Assessment |
| ||
| nasopharyngeal carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-systematic Assessment |
| ||
| psychiatric inpatient hospitalization | Psychiatric disorders | Non-systematic Assessment |
| ||
| vitreal hemmorhage | Eye disorders | Non-systematic Assessment |
| ||
| bacteremia | Infections and infestations | Non-systematic Assessment |
| ||
| puncture wound | Injury, poisoning and procedural complications | Non-systematic Assessment |
| ||
| nephrotic syndrome | Renal and urinary disorders | Non-systematic Assessment |
| ||
| Lower GI bleed | Gastrointestinal disorders | Non-systematic Assessment |
| ||
| glaucoma | Eye disorders | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| headache | Nervous system disorders | Systematic Assessment |
| ||
| GI | Gastrointestinal disorders | Systematic Assessment |
| ||
| Other AE | Investigations | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Ildiko Lingvay | UT Southwestern Medical Center | 214-648-2779 | ildiko.lingvay@utsouthwestern.edu |
| Oct 1, 2019 |
| Prot_SAP_000.pdf |
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D003920 | Diabetes Mellitus |
| D007333 | Insulin Resistance |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D006946 | Hyperinsulinism |
Not provided
Not provided
| ID | Term |
|---|---|
| D008687 | Metformin |
| D000069057 | Insulin Detemir |
| D000069450 | Liraglutide |
| D061267 | Insulin Aspart |
| ID | Term |
|---|---|
| D001645 | Biguanides |
| D006146 | Guanidines |
| D000578 | Amidines |
| D009930 | Organic Chemicals |
| D049528 | Insulin, Long-Acting |
| D061385 | Insulins |
| D010187 | Pancreatic Hormones |
| D036361 | Peptide Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D052216 | Glucagon-Like Peptide 1 |
| D004763 | Glucagon-Like Peptides |
| D052336 | Proglucagon |
| D005768 | Gastrointestinal Hormones |
| D061266 | Insulin, Short-Acting |
Not provided
Not provided
| Male |
|
| Non-Hispanic White |
|
| African-American |
|
|
|
|
|
|
|
|
|
|
|
Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol"; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day) Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day) Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed. Liraglutide: Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached |
|
|
|
|